BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
about
The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancerTargeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma CellsA c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2Cyclin Dependent Kinase 9 Inhibitors for Cancer TherapyTargeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.Emerging drug profile: cyclin-dependent kinase inhibitorsCyclin-dependent kinase inhibitors closer to market launch?Sulfoximines: a neglected opportunity in medicinal chemistry.Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).Inhibitors of cyclin-dependent kinases as cancer therapeutics.N-cyano sulfoximines: COX inhibition, anticancer activity, cellular toxicity, and mutagenicity.Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.Effects of roniciclib in preclinical models of anaplastic thyroid cancer.Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides.Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.Access to N-cyanosulfoximines by transition metal-free iminations of sulfoxides.Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides.Activity of roniciclib in medullary thyroid cancer.The Synthesis of Chiral Benzothiazine and Thiazinoquinoline DerivativesSulfoxide-to-Sulfilimine Conversions: Use of Modified Burgess-Type Reagents
P2860
Q27684613-CDD523B9-7674-4929-85A6-1A0227BF882DQ28554501-6A575378-C8B1-41A4-932C-048081BC9D26Q33669451-C48018BD-C3C8-4104-891F-6465F667776FQ35722786-98F1B65D-6AAD-423D-8E39-9A3CE60376E8Q36015334-7CCB3573-27C4-4F55-BB97-D1966284AC05Q36280842-D22F34A2-80CB-4F1B-B272-56F82547B4B8Q37185372-9E05AD1F-DE42-4F78-840D-B1ADF96D1BFFQ38100203-D9306F32-3FC4-4491-8A2B-C2DB03EBFE8FQ38128269-541FFCDD-5010-49EF-8B6C-74DB0631C6A1Q38248633-6C83E3EC-8D88-49FB-97F5-F41D828F4CD8Q38538589-FFC824EB-A395-4CC8-8CE4-19085132FAA7Q38806786-920A29A3-38BC-4735-87C5-354CAA33DD1FQ38812815-A8B8BAA0-5AC1-4563-B2FC-16C0202E02F5Q38949247-A452DFF1-3F1A-405A-B12E-0E60A40867A8Q39125016-4C8D2C35-789F-41E5-9FDF-6948B2A7A7CDQ39229336-EB1E3B37-13C3-4C2A-879F-F50FDC56DB73Q41039819-817DD13A-7D8C-4CAF-A43E-B2AB75359E20Q42366591-43D3AC06-E392-4468-BC0C-76F6BD95E9B2Q42739081-7B5B30CE-00BF-4424-8CEC-7C4C36778B9EQ45058232-A56620C6-B0A9-4897-BE25-096169F76A5DQ45767567-D7332FBB-0ACD-4FD9-A5F0-F6202F173BC8Q46420204-149324D3-C091-41F0-B374-F28EBEC0FC53Q48364779-86E329C9-CFFB-4180-A987-7571D00C731AQ49536215-A53271E4-F494-48B3-A281-9BE81FA8760DQ50932257-861819DD-A561-4198-AE9F-5BDA213352CDQ52803327-0661B674-0831-40EA-8730-810251BD243BQ55363491-C0353BF0-BE21-48A0-A92E-E81ED2EB416BQ57404750-9BDB6315-68D8-4EAE-B31A-A15BA51FFDBEQ57404785-4F1F908B-5844-47A8-9F31-C1F392088F5A
P2860
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
BAY 1000394, a novel cyclin-de ...... eatment upon oral application.
@en
BAY 1000394, a novel cyclin-de ...... eatment upon oral application.
@nl
type
label
BAY 1000394, a novel cyclin-de ...... eatment upon oral application.
@en
BAY 1000394, a novel cyclin-de ...... eatment upon oral application.
@nl
prefLabel
BAY 1000394, a novel cyclin-de ...... eatment upon oral application.
@en
BAY 1000394, a novel cyclin-de ...... eatment upon oral application.
@nl
P2093
P1476
BAY 1000394, a novel cyclin-de ...... eatment upon oral application.
@en
P2093
Antje M Wengner
Christoph Schatz
Dominik Mumberg
Gerhard Siemeister
Karl Ziegelbauer
Philip Lienau
Ulrich Lücking
Wolfram Steinke
P304
P356
10.1158/1535-7163.MCT-12-0286
P577
2012-07-19T00:00:00Z